Solara Active Pharma Sciences Limited

NSEI:SOLARA Voorraadrapport

Marktkapitalisatie: ₹36.6b

Solara Active Pharma Sciences Beheer

Beheer criteriumcontroles 0/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Poorvank Purohit

Algemeen directeur

₹39.8m

Totale compensatie

Percentage CEO-salaris72.9%
Dienstverband CEO1.8yrs
Eigendom CEOn/a
Management gemiddelde ambtstermijn1.8yrs
Gemiddelde ambtstermijn bestuur1.3yrs

Recente managementupdates

Recent updates

The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Sep 13
The Market Lifts Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares 26% But It Can Do More

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Jul 20
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 30% Bounce

Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

Jun 05
Slammed 32% Solara Active Pharma Sciences Limited (NSE:SOLARA) Screens Well Here But There Might Be A Catch

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

May 11
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Apr 19
Investors Still Aren't Entirely Convinced By Solara Active Pharma Sciences Limited's (NSE:SOLARA) Revenues Despite 28% Price Jump

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Mar 13
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Feb 23
Even With A 26% Surge, Cautious Investors Are Not Rewarding Solara Active Pharma Sciences Limited's (NSE:SOLARA) Performance Completely

Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Jan 04
Further Upside For Solara Active Pharma Sciences Limited (NSE:SOLARA) Shares Could Introduce Price Risks After 25% Bounce

Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

May 12
Solara Active Pharma Sciences Limited's (NSE:SOLARA) Intrinsic Value Is Potentially 81% Above Its Share Price

Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Nov 08
Estimating The Intrinsic Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Sep 30
Is Solara Active Pharma Sciences (NSE:SOLARA) A Risky Investment?

Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Aug 03
Are Investors Undervaluing Solara Active Pharma Sciences Limited (NSE:SOLARA) By 22%?

Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Jun 19
Solara Active Pharma Sciences (NSE:SOLARA) Is Making Moderate Use Of Debt

Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17
Newsflash: Solara Active Pharma Sciences Limited (NSE:SOLARA) Analysts Have Been Trimming Their Revenue Forecasts

A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Dec 21
A Look At The Fair Value Of Solara Active Pharma Sciences Limited (NSE:SOLARA)

Analyse CEO-vergoeding

Hoe is Poorvank Purohit's beloning veranderd ten opzichte van Solara Active Pharma Sciences's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-₹5b

Jun 30 2024n/an/a

-₹6b

Mar 31 2024₹40m₹29m

-₹6b

Dec 31 2023n/an/a

-₹3b

Sep 30 2023n/an/a

-₹325m

Jun 30 2023n/an/a

-₹253m

Mar 31 2023₹5mn/a

-₹222m

Compensatie versus markt: De totale vergoeding ($USD 471.43K ) Poorvank } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 273.81K ).

Compensatie versus inkomsten: De vergoeding van Poorvank is gestegen terwijl het bedrijf verliesgevend is.


CEO

Poorvank Purohit (45 yo)

1.8yrs

Tenure

₹39,800,000

Compensatie

Mr. Poorvank Purohit serves as Chief Executive Officer of Solara Active Pharma Sciences Limited since February 03, 2023 and serves as its Director & Managing Director since July 2023. He started his career...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Poorvank Purohit
MD, CEO & Director1.8yrs₹39.80mgeen gegevens
Arun Baskaran
Chief Financial Officerless than a year₹700.00kgeen gegevens
Mohan Muthunarayanan
COO & Executive Director2.3yrs₹3.80mgeen gegevens
Suddapalli Krishna
Company Secretary6.7yrs₹4.80mgeen gegevens
Arun Pillai
Founder & Non-Executive Directorno datageen gegevens5.71%
₹ 2.1b
Hero Velladurai
Chief Scientific Officerless than a yeargeen gegevensgeen gegevens
V. Moorthy
Chief Quality Officerno datageen gegevensgeen gegevens

1.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van SOLARA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.


Bestuursleden

NaamPositieTenureCompensatieEigendom
Poorvank Purohit
MD, CEO & Director1.3yrs₹39.80mgeen gegevens
Mohan Muthunarayanan
COO & Executive Directorless than a year₹3.80mgeen gegevens
Arun Pillai
Founder & Non-Executive Director3.3yrsgeen gegevens5.71%
₹ 2.1b
Manish Gupta
Non-Executive Directorless than a yeargeen gegevensgeen gegevens
Kausalya Santhanam
Independent Director6.6yrs₹1.50mgeen gegevens
Ramakrishnan Rajagopal
Independent Chairman6.6yrs₹1.50m0.010%
₹ 3.8m
Rajendra Srivastava
Independent Directorless than a year₹200.00kgeen gegevens
Kartheek Raju
Non-Executive Non-Independent Director3.3yrsgeen gegevensgeen gegevens
Rajiv Nabar
Independent Directorless than a year₹400.00kgeen gegevens

1.3yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van SOLARA wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw bestuur.